- Home
- GOSS vs DYNX Comparison
GOSS vs DYNX Comparison
Compare GOSS & DYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- DYNX
- Stock Information
- Founded
- GOSS 2015
- DYNX 2024
- Country
- GOSS United States
- DYNX United States
- Employees
- GOSS N/A
- DYNX N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- DYNX
- Sector
- GOSS Health Care
- DYNX
- Exchange
- GOSS Nasdaq
- DYNX NYSE
- Market Cap
- GOSS 188.6M
- DYNX 220.4M
- IPO Year
- GOSS 2019
- DYNX 2024
- Fundamental
- Price
- GOSS $0.84
- DYNX $9.95
- Analyst Decision
- GOSS Strong Buy
- DYNX
- Analyst Count
- GOSS 4
- DYNX 0
- Target Price
- GOSS $7.50
- DYNX N/A
- AVG Volume (30 Days)
- GOSS 1.5M
- DYNX 46.0K
- Earning Date
- GOSS 05-06-2025
- DYNX 01-01-0001
- Dividend Yield
- GOSS N/A
- DYNX N/A
- EPS Growth
- GOSS N/A
- DYNX N/A
- EPS
- GOSS N/A
- DYNX N/A
- Revenue
- GOSS $114,701,000.00
- DYNX N/A
- Revenue This Year
- GOSS N/A
- DYNX N/A
- Revenue Next Year
- GOSS $172.31
- DYNX N/A
- P/E Ratio
- GOSS N/A
- DYNX N/A
- Revenue Growth
- GOSS N/A
- DYNX N/A
- 52 Week Low
- GOSS $0.50
- DYNX $9.78
- 52 Week High
- GOSS $1.55
- DYNX $10.48
- Technical
- Relative Strength Index (RSI)
- GOSS 37.58
- DYNX N/A
- Support Level
- GOSS $0.80
- DYNX N/A
- Resistance Level
- GOSS $0.88
- DYNX N/A
- Average True Range (ATR)
- GOSS 0.10
- DYNX 0.00
- MACD
- GOSS -0.01
- DYNX 0.00
- Stochastic Oscillator
- GOSS 20.24
- DYNX 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About DYNX DYNAMIX CORP
Dynamix Corp is a blank check company.